SynOx Therapeutics Limited is a late-stage clinical biopharmaceutical firm situated in Oxford, UK and Dublin, Ireland. It is developing emactuzumab for the treatment of many disorders, including Tenosynovial Giant Cell Tumour (TGCT). The company has secured up to $35 million in debt capital.
Investors
- Hercules Capital
- Inc. (NYSE: HTGC)
- They also contributed to the most recent $75 million Series B investment.
The funds will be utilized by the firm to further strengthen its financial sheet as it conducts TANGENT, a registrational Phase 3 study of emactuzumab, a monoclonal antibody (mAb) that inhibits CSF-1(R) and is used to treat TGCT.
Emactuzumab is a monoclonal antibody against CSF-1R that SynOx Therapeutics, a late-stage clinical biopharmaceutical business led by CEO Ray Barlow, is developing for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other illnesses linked to CSF-1 and macrophages.
“This financing will provide SynOx the extra funds it needs to accomplish its goals of making emactuzumab a best-in-class medication, addressing major unmet medical needs, and significantly improving the quality of life for as many people as possible. We appreciate Hercules’ support, which, along with the $75 million we just received in our Series B round, places SynOx in a solid financial position.”
Ray Barlow
Concerning SynOx Therapeutics
Emactuzumab, a best-in-class monoclonal antibody against CSF-1R, is being developed by SynOx Therapeutics Limited, a late-stage clinical biopharmaceutical business with offices in Oxford and Dublin, to treat Tenosynovial Giant Cell Tumour (TGCT) and other CSF-1-related and macrophage-driven illnesses. A seasoned group of business experts with a proven track record of creating and launching products is in charge of SynOx. A powerful syndicate of leading life science investors, including Medicxi, Hercules Capital, Inc., Forbion, HealthCap, and BioQube, supports it.
